One small investment into these three companies at IPO and you’ve outperformed almost any other investment you could make. Unfortunately, you can’t go back in time and invest in what became the three most dominant companies in the tech world.

Frank Holler Biography and Net Worth

Director of Xenon Pharmaceuticals

Frank A. Holler serves as Independent Director of the Company. Mr. Holler previously served as Xenon’s President and CEO from 1999 to 2003. Mr. Holler has served as director and chairman of Sernova Corporation, a publicly-traded biotechnology company, since 2014. He has also served as a director and chairman of Harvest One Cannabis Inc., a publicly-traded cannabis company, since September 2018. Mr. Holler previously served as chairman and CEO at BC Advantage Funds (VCC) Ltd., a venture capital firm and publicly-traded company that invested in emerging life science, clean tech and information technology companies, from 2004 to 2016. Mr. Holler also previously served on the board of directors of publicly-traded companies including Protox Therapeutics (now Sophiris Bio) from 2005 to 2012, Aquinox Pharmaceuticals, Inc. from 2010 to 2014 and Allon Therapeutics from 2005 to 2013. He also served as chair of the Audit Committee and chair of the Investment Committee for Genome BC, a large publicly funded research organization, from 2005 to 2011. In addition, Mr. Holler served as President and CEO of ID Biomedical Corporation from 1991 to 1998, and was a founding director of Angiotech Pharmaceuticals from 1992 to 1997. Mr. Holler was an Investment Banker with Wood Gundy Inc. (now CIBC World Markets) from 1984 to 1988 and Merrill Lynch Canada from 1988 to 1989. Mr. Holler holds a B.A. in Economics and an M.B.A. from the University of British Columbia. Our Board believes Mr. Holler is qualified to serve on our Board because of his experience as a biotechnology entrepreneur and venture capitalist, his investment banking experience, and his knowledge and perspective of the Corporation.

What is Frank A. Holler's net worth?: The estimated net worth of Frank A. Holler is at least $4.79 million as of May 27th, 2021. Holler owns 125,127 shares of Xenon Pharmaceuticals stock worth more than $4,793,615 as of November 18th. This net worth evaluation does not reflect any other assets that Holler may own. Learn More about Frank A. Holler's net worth.
How do I contact Frank A. Holler?: The corporate mailing address for Holler and other Xenon Pharmaceuticals executives is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. Xenon Pharmaceuticals can also be reached via phone at (604) 484-3300 and via email at [email protected]. Learn More on Frank A. Holler's contact information.
Has Frank A. Holler been buying or selling shares of Xenon Pharmaceuticals?: Frank A. Holler has not been actively trading shares of Xenon Pharmaceuticals during the past quarter. Most recently, Frank A. Holler sold 11,064 shares of the business's stock in a transaction on Thursday, May 27th. The shares were sold at an average price of $18.68, for a transaction totalling $206,675.52. Following the completion of the sale, the director now directly owns 125,127 shares of the company's stock, valued at $2,337,372.36. Learn More on Frank A. Holler's trading history.
Who are Xenon Pharmaceuticals' active insiders?: Xenon Pharmaceuticals' insider roster includes James Empfield (EVP), Steven Gannon (Director), Frank Holler (Director), Christopher Kenney (Insider), Ian Mortimer (President and Chief Executive Officer), Gary Patou (Director), Simon Pimstone (Director), Robin Sherrington (EVP), Dawn Svoronos (Director), and Christopher Von Seggern (Insider). Learn More on Xenon Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Xenon Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 31,517 shares worth more than $1,379,060.56. The most recent insider tranaction occured on March, 7th when EVP Sherrington Robin sold 7,137 shares worth more than $330,300.36. Insiders at Xenon Pharmaceuticals own 5.5% of the company. Learn More about insider trades at Xenon Pharmaceuticals.
Information on this page was last updated on 3/7/2024.

Frank A. Holler Insider Trading History at Xenon Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/27/2021	Sell	11,064	$18.68	$206,675.52	125,127
9/19/2019	Sell	7,600	$9.27	$70,452.00	124,161
9/17/2019	Sell	5,069	$9.32	$47,243.08	136,129
12/15/2016	Sell	30,000	$7.85	$235,500.00	115,869
8/19/2016	Sell	11,938	$7.65	$91,325.70	145,869
8/18/2016	Sell	18,062	$7.93	$143,231.66	169,006

Frank A. Holler Buying and Selling Activity at Xenon Pharmaceuticals

Xenon Pharmaceuticals Company Overview

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Today's Range

Now: $38.31

$37.38

$40.04

50 Day Range

MA: $41.21

$38.06

$45.74

2 Week Range

Now: $38.31

$28.20

$50.99

Volume

878,189 shs

Average Volume

389,378 shs

Market Capitalization

$2.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25

I was wrong. Dead wrong.

From Porter & Company | Ad

Click here to watch.